Key Questions 1. For outpatients with depressive, anxiety, and/or premenstrual dysphoric disorders, do second-generation antidepressants differ in efficacy or effectiveness? 2. For outpatients with depressive, anxiety, and/or premenstrual dysphoric disorders, do second-generation antidepressants differ in harms or adverse events? 3. Are there subgroups of patients based on demographics (age, racial groups, socio-demographic factors, and sex), other medications, or comorbidities for which one second-generation antidepressant is more effective or associated with fewer adverse events than another?